Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300146 | 0.81 | KMT2A (0.47) | ALDH1A1MEN1KMT2ACYP1A2MAPT | |
| SCHEMBL27561346 | 0.81 | CYSLTR2 (0.48) | CYP1A2CYSLTR1LMNATSHRCYSLTR2 | |
| SCHEMBL30009200 | 0.81 | BACE1 (0.46) | CYP1A2MAPTCYSLTR1GLACYSLTR2 | |
| SCHEMBL140815 | 0.78 | CYP1A2 (0.65) | ALDH1A1MEN1KMT2ACYP1A2GPBAR1 | |
| Anthracene SCHEMBL10418177 | 0.77 | CYP1A2 (0.59) | ALDH1A1MEN1KMT2ACYP1A2GPBAR1 | |
| SCHEMBL29970876 | 0.76 | MEN1 (0.46) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| Acetic Acid SCHEMBL27459479 | 0.74 | CYP1A2 (0.64) | ALDH1A1MEN1KMT2ACYP1A2RAB9A | |
| SCHEMBL14610935 | 0.72 | CCR1 (0.54) | CAMK2ACA2ALDH1A1CYP1A2GAA | |
| Sulfuric Acid SCHEMBL28294784 | 0.72 | CYP1A2 (0.58) | ALDH1A1MEN1KMT2ACYP1A2GPBAR1 | |
| SCHEMBL1641523 | 0.72 | HDAC1 (0.52) | ALDH1A1MEN1KMT2ACYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20180243328-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | CAMK2A 3305/4885CA2 4724/4885ALDH1A1 2514/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | CAMK2A 3224/4885CA2 4691/4885ALDH1A1 2287/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | CAMK2A 3285/4885CA2 4675/4885ALDH1A1 2200/4885 |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | CAMK2A 2604/4885CA2 4141/4885ALDH1A1 3170/4885 |
| US-20180243328-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | CAMK2A 3305/4885CA2 4724/4885ALDH1A1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.